CRMD Stock Down 9% Despite Q3 Earnings and Revenues Beat Estimates

Zacks
Abrir em Zacks
CRMD Stock Down 9% Despite Q3 Earnings and Revenues Beat Estimates

CorMedix Therapeutics CRMD reported an adjusted loss of 4 cents per share in the third quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 9 cents. The company reported adjusted earnings of 57 cents per share in the year-ago quarter. These figures exclude non-recurring items.

Consolidated revenues of about $54.5 million declined almost 48% from $104.3 million a year earlier but beat the Zacks Consensus Estimate of $52 million. DefenCath's transition to lower post-TDAPA net pricing drove the decline, even as large dialysis customers largely maintained utilization. CRMD stock declined 8.7% following the earnings release, reflecting concerns over lower realized prices for DefenCath.

CRMD's DefenCath Sales Face Post-TDAPA Pressure

DefenCath generated $17.2 million in third-quarter net sales, down 74% sequentially from the preceding quarter. The decline primarily reflected lower net pricing following the product's transition to the post-TDAPA reimbursement period on July 1, 2026. Large outpatient dialysis customers largely maintained utilization despite the reimbursement change.

DefenCath revenues included a $5-million favorable adjustment to estimates for Medicaid rebates and product returns. Management said actual Medicaid utilization and product returns were below earlier expectations. The adjustment boosted reported sales even as reduced reimbursement weighed on underlying revenues.

CorMedix's Melinta Portfolio Supports Sales

CorMedix’s remaining portfolio accounted for $37.3 million of the quarter's $54.5 million in consolidated revenues. This included $31.4 million in product sales and roughly $5.9 million in contract revenues and grant income under its BARDA agreement.

The Melinta acquisition closed in August last year. Consequently, the year-ago quarter included only one month of Melinta operations compared with a full quarter in 2026. Management described Vabomere and Minocin as relatively durable products, with occasional low-single-digit growth. Meanwhile, Kimyrsa and Orbactiv faced pressure following the launch of generic Dalvance in 2025.

Shares of CorMedix have plunged 58.4% so far this year against the industry’s 10.4% growth.

Zacks Investment Research
Image Source: Zacks Investment Research

CRMD's Costs Decline on Lower Integration Expenses

Total operating expenses fell about 12% year over year to $36.6 million in the third quarter. The reduction mainly reflected transaction, integration and reorganization costs incurred following the Melinta acquisition in 2025, partly offset by a full quarter of costs for the expanded business in 2026.

Research and development expenses increased 37.3% year over year to $7 million, driven by higher personnel and clinical study costs. Selling and marketing expenses rose 4.5% year over year to $11.7 million, reflecting investments in the larger portfolio. General and administrative expenses decreased 29.8% to $17.9 million, mainly due to lower Melinta-related transaction and integration costs.

CorMedix ended the third quarter of 2026 with $355.2 million in cash and cash equivalents, excluding restricted cash compared with $256.7 million at the end of the second quarter.

CorMedix Holds Revenue View, Narrows EBITDA Outlook

Management maintained its full-year 2026 consolidated revenue guidance of $325-$345 million. It narrowed adjusted EBITDA guidance to $130-$140 million from $125-$140 million and lowered cash-based operating expense guidance to $140-$145 million from $145-$155 million.

However, CorMedix deferred its 2027 DefenCath revenue guidance until early 2027, citing uncertainty over quarterly changes to Medicare reimbursement. The Centers for Medicare & Medicaid Services set the first-quarter 2027 add-on payment at $8.32 but adopted a quarterly reset mechanism. Management expects the full-year average to be below $8.32 but at least double the current $2.37 rate. It continues discussions with customers and Medicare Advantage plans about pricing and reimbursement.

CRMD's Key Updates

The FDA accepted the supplemental new drug application for Rezzayo to prevent invasive fungal disease in certain immunosuppressed transplant patients, granting priority review in October. The application follows positive phase III ReSPECT study results, with regulatory action expected in the first quarter of 2027. If approved, Rezzayo's label would expand beyond its current indication for treating candidemia and invasive candidiasis in adults and pediatric patients aged 12 years and older with limited or no alternative treatment options. CorMedix plans to begin promotional efforts in the second half of 2027, subject to approval.

Enrollment in the phase III DefenCath study for patients receiving total parenteral nutrition remains significantly behind schedule despite additional study sites and a protocol amendment. The company is evaluating alternative regulatory pathways if enrollment does not improve and expects to determine its strategy before the next quarterly update.

Earlier in November, CorMedix announced an agreement to acquire substantially all assets of Heron Therapeutics, including four commercial products, Zynrelef, Aponvie, Cinvanti and Sustol. These products complement CorMedix's existing portfolio by expanding its presence across acute care and oncology supportive care. The acquisition is expected to close in the first quarter of 2027, subject to Heron stockholder approval, regulatory clearance and other customary closing conditions. Management expects the acquired portfolio to contribute $125-$150 million in revenues in 2027, effectively doubling its non-DefenCath revenue base. The transaction is expected to be immediately accretive to earnings and free cash flow upon closing.

CorMedix Inc Price, Consensus and EPS Surprise

CorMedix Inc Price, Consensus and EPS Surprise

CorMedix Inc price-consensus-eps-surprise-chart | CorMedix Inc Quote

CRMD’s Zacks Rank & Stocks to Consider

CorMedix currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are Amneal Pharmaceuticals AMRX, AC Immune ACIU and Adaptive Biotechnologies ADPT. AMRX sports a Zacks Rank #1 (Strong Buy), while ACIU and ADPT carry a Zacks Rank #2 (Buy) each at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 30 days, earnings per share estimates for Amneal Pharmaceuticals have increased from $1.03 to $1.06 for 2026. Over the same period, estimates for 2027 earnings per share have risen from $1.16 to $1.21. AMRX’s shares have climbed 72.2% year to date.

Amneal Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 27.21%.

Over the past 30 days, loss per share estimates for AC Immune have narrowed from 60 cents to 54 cents for 2026. Over the same period, estimates for 2027 earnings per share have increased from 17 cents to 43 cents. ACIU’s shares have plunged 31.9% year to date.

AC Immune’s earnings beat estimates in each of the trailing four quarters, with an average surprise of 37.79%.

Over the past 30 days, loss per share estimates for Adaptive Biotechnologies have narrowed from 55 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have also improved from 17 cents to 3 cents. ADPT’s shares have surged 81.5% year to date.

Adaptive Biotechnologies’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 53.62%.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
CorMedix Inc (CRMD): Free Stock Analysis Report
 
Adaptive Biotechnologies Corporation (ADPT): Free Stock Analysis Report
 
AC Immune (ACIU): Free Stock Analysis Report
 
AMNEAL PHARMACEUTICALS, INC. (AMRX): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research